Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Article CommentaryCommentary

Cannabis in the workplace

What physicians need to know

Brent Wolfrom and Victor K. Ng
Canadian Family Physician May 2020, 66 (5) 317-318;
Brent Wolfrom
Postgraduate Program Director in the Department of Family Medicine at Queen’s University in Kingston, Ont, and Veterans’ Health Observer for the Occupational Medicine Community of Practice of the College of Family Physicians of Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: brent.wolfrom@dfm.queensu.ca
Victor K. Ng
Physician advisor in the Professional Development and Practice Support division of the College of Family Physicians of Canada and Assistant Professor in family and emergency medicine at the University of Toronto in Ontario and at Western University in London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Cannabis for recreational use was legalized in Canada on October 17, 2018.1 Since that time there has been much discussion on the potential health effects of its use and the implications of legalization for public health and safety. Potential health effects, including psychosis and cardiovascular risk, have been suggested.2,3 However, at this time there is little to inform physicians about the effects of cannabis on workers or workplaces.

While a variety of industries and organizations have now published guidance on the implications of cannabis use for the workplace, these policies, while based on the same available evidence, contain highly disparate recommendations. For instance, the Vancouver Police Department allows their police officers to consume cannabis at any time while off duty as long as they arrive for their shift able to complete their duties, whereas the Calgary Police Service has instituted an outright ban on cannabis use for their members.4 In contrast, the Canadian Armed Forces has taken a more nuanced approach and instituted direction ranging from 8 hours of abstinence before duty up to a complete ban depending on the individual Canadian Armed Forces members’ duties and location.5 More generally, the Occupational and Environmental Medical Association of Canada has published a position paper on cannabis use for safety-sensitive work wherein they recommend against operating motor vehicles or equipment or engaging in other safety-sensitive tasks for 24 hours after cannabis consumption, or for longer if impairment persists.6 Similarly, the Canadian Centre for Occupational Health and Safety has also released recommended workplace strategies for dealing with impairment caused by cannabis, including training supervisors to recognize the signs of impairment.7

Some of our patients work in industries or organizations with current and focused polices relevant to recreational drug use, in which case they might receive some level of guidance on cannabis or other recreational drugs. However, for many of our patients that is not the case, and it will fall to their physicians to provide guidance. While this might be a daunting task for us, it also emphasizes the importance of occupational medicine within family medicine. We should also pause and consider the effects of other drugs, including prescribed medications, on our patients in the workplace.

What do we know about the risks of impairment?

The scientific data pertaining to cannabis are growing rapidly; however, the determination of impairment after consumption is elusive. This uncertainty is exacerbated by differing pharmacokinetics depending on route of administration and apparent differences between chronic and intermittent users.8 Indeed, bioavailability was found to be between 2% and 56% through the inhalation route alone, with bioavailability through oral consumption likely even more variable owing to differing rates of absorption and first-pass metabolism.9 In general, psychotropic effects occur within minutes of inhalation and last for 2 to 4 hours, whereas psychotropic effects from oral consumption typically occur within 30 to 60 minutes and last for up to 12 hours.9,10

So what do we know about the risks of cannabis impairment in the workplace? Many of the current data are epidemiologic, with few controlled trials. Postal workers who tested positive for cannabis on enrolment drug screening had 55% more industrial accidents, 85% more injuries, and 75% higher absenteeism than those who tested negative.9 These are large numbers but they hardly show a clear cause and effect. There are very compelling data to suggest that acute cannabis consumption is associated with an increased risk of motor vehicle collisions, especially fatal collisions.11,12 Of note, regular cannabis users made more driving errors than nonregular users did, suggesting that there might be an increased risk with chronic use, at least when combined with alcohol use.8 Importantly, a recent Canadian study found cannabis use to be associated with a 4-fold increased risk of being involved in a motor vehicle collision.13

A more controlled study involving airline pilots demonstrated impairments in aircraft landings 24 hours after smoking a cigarette containing 19 mg of tetrahydrocannabinol. Of interest, the pilots reported no awareness of impairment.14 This lack of awareness of impairment would seem to correspond with data from the Canadian Cannabis Survey that found, among respondents who used cannabis in the previous 12 months, 39% reported driving within 2 hours of consumption, with 29% of those having done so 10 or more times within the past 12 months. It is not surprising, then, that 18% reported using cannabis at or before work.15 Similar data are available out of the United States, where a trend toward decreased perception of risks associated with cannabis is correlated with an increase in its use.16

What about risks from other medications?

As the use of cannabis increases, and its use becomes more acceptable and openly discussed, physicians will be required to become increasingly knowledgeable about its effects. Many commonly prescribed medications carry similar risks. For instance, study participants tested the morning after taking 7.5 mg of zopiclone were found to demonstrate a level of impairment worse than a blood alcohol level of 0.05%.17 The International Council on Alcohol, Drugs and Traffic Safety has developed a categorization system that provides specific recommendations to assist physicians in determining the risk of driving while taking certain medications. International Council on Alcohol, Drugs and Traffic Safety category III medications are considered likely to produce severe effects or are presumed to be potentially dangerous. Many frequently taken category III medications affected study participants in driving tests in ways that were equivalent to having a blood alcohol concentration of greater than 0.08%. Examples of category III medications include benzodiazepines, z drugs, amitriptyline, trazodone, mirtazapine, and diphenhydramine.18 These are all medications that are commonly prescribed with little thought of the risks of impairment they cause. All impairing substances, including cannabis, should be assessed in the same manner for risks and benefits by physicians who have patients taking them. Further, when physicians recommend cannabis for medical reasons, we must be aware of its potential effects on safety-sensitive work.

Conclusion

As the legalization of cannabis in Canada has presented a challenge for physicians, perhaps it has also provided an opportunity for reframing our thoughts about impairment. Impairment might be a result of illness; drugs that are illicit, prescribed, or legally acquired for recreation; fatigue; or distraction, among other causes. Cannabis legalization might also present an opportunity to refocus on the importance of occupational health in our patients’ well-being and in their workplaces, and workplaces’ effects on our patients’ health. In the meantime, the Centre for Effective Practice has published a useful resource for physicians on nonmedical cannabis use.19

Footnotes

  • Competing interests None declared

  • The opinions expressed in commentaries are those of the authors. Publication does not imply endorsement by the College of Family Physicians of Canada.

  • This article has been peer reviewed.

  • La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de mai 2020 à la page e140.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    Cannabis Act. S.C. 2018. p. 16. Available from: https://laws-lois.justice.gc.ca/eng/acts/C-24.5/. Accessed 2020 Mar 30.
  2. 2.↵
    1. Singh A,
    2. Saluja S,
    3. Kumar A,
    4. Agrawal S,
    5. Thind M,
    6. Nanda S,
    7. et al
    . Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther 2018;7(1):45-59. Epub 2017 Dec 7.
    OpenUrl
  3. 3.↵
    1. Marconi A,
    2. Di Forti M,
    3. Lewis CM,
    4. Murray RM,
    5. Vassos E
    . Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016;42(5):1262-9. Epub 2016 Feb 15.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Furlan A,
    2. Carnide N
    . Cannabis in the workplace: we need an accurate measure of impairment. The Conversation 2018 Oct 16. Available from: http://theconversation.com/cannabis-in-the-workplacewe-need-an-accurate-measure-of-impairment-89142. Accessed 2020 Mar 27.
  5. 5.↵
    1. Department of National Defence
    . Defence Administrative Orders and Directives (DAOD) – 2000. DAOD2007-2, Use of Cannabis by DND Employees. Ottawa, ON: Government of Canada; 2018. Available from: https://www.canada.ca/en/department-national-defence/corporate/policies-standards/defence-administrative-orders-directives/2000-series/2007/2007-2-use-cannabis-dnd-employees.html#pro. Accessed 2020 Mar 27.
  6. 6.↵
    1. Els C,
    2. Jackson TD,
    3. Aidoo H,
    4. Wyatt G,
    5. Sowah D,
    6. Chao D,
    7. et al
    . Position statement on the implications of cannabis use for safety-sensitive work. Winnipeg, MB: bookOccupational and Environmental Medical Association of Canada; 2018. Available from: https://oemac.org/wp-content/uploads/2018/09/Position-Statement-on-the-Implications-of-cannabis-use.pdf. Accessed 2020 Mar 27.
  7. 7.↵
    1. Canadian Centre for Occupational Health and Safety
    . Workplace strategies: risk of impairment from cannabis. 3rd ed. Hamilton, ON: Canadian Centre for Occupational Health and Safety; 2018. Available from: https://www.ccohs.ca/products/publications/cannabis_whitepaper.pdf. Accessed 2020 Mar 27.
  8. 8.↵
    1. Fischer B,
    2. Russell C,
    3. Sabioni P,
    4. van den Brink W,
    5. Le Foll B,
    6. Hall W,
    7. et al
    . Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health 2017;107(8):e1-12. Epub 2017 Jun 23. Erratum in: Am J Public Health 2018;108(5):e2.
    OpenUrl
  9. 9.↵
    1. Goldsmith RS,
    2. Targino MC,
    3. Fanciullo GJ,
    4. Martin DW,
    5. Hartenbaum NP,
    6. White JM,
    7. et al
    . Medical marijuana in the workplace: challenges and management options for occupational physicians. J Occup Environ Med 2015;57(5):518-25.
    OpenUrl
  10. 10.↵
    1. Monte AA,
    2. Zane RD,
    3. Heard KJ
    . The implications of marijuana legalization in Colorado. JAMA 2015;313(3):241-2.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Asbridge M,
    2. Hayden JA,
    3. Cartwright JL
    . Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012;344:e536.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Liguori A,
    2. Gatto CP,
    3. Robinson JH
    . Effects of marijuana on equilibrium, psychomotor performance, and simulated driving. Behav Pharmacol 1998;9(7):599-609.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Asbridge M,
    2. Mann R,
    3. Cusimano MD,
    4. Trayling C,
    5. Roerecke M,
    6. Tallon JM,
    7. et al
    . Cannabis and traffic collision risk: findings from a case-crossover study of injured drivers presenting to emergency departments. Int J Public Health 2014;59(2):395-404. Epub 2013 Sep 24.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Yesavage JA,
    2. Leirer VO,
    3. Denari M,
    4. Hollister LE
    . Carry-over effects of marijuana intoxication on aircraft pilot performance: a preliminary report. Am J Psychiatry 1985;142(11):1325-9.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Government of Canada
    . Canadian Cannabis survey 2017—summary. Ottawa, ON: Government of Canada; 2017. Available from: https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/canadian-cannabis-survey-2017-summary.html. Accessed 2020 Mar 27.
  16. 16.↵
    1. Volkow ND,
    2. Baler RD,
    3. Compton WM,
    4. Weiss S
    . Adverse health effects of marijuana use. N Engl J Med 2014;370(23):2219-27.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Mets MA,
    2. de Vries JM,
    3. de Senerpont Domis LM,
    4. Volkerts ER,
    5. Olivier B,
    6. Verster JC
    . Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep 2011;34(10):1327-34.
    OpenUrlPubMed
  18. 18.↵
    1. Verster JC,
    2. Mets MA
    . Psychoactive medication and traffic safety. Int J Environ Res Public Health 2009;6(3):1041-54. Epub 2009 Mar 10.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Centre for Effective Practice
    . Non-medical cannabis resource: Ontario. Toronto, ON: Centre for Effective Practice; 2018. Available from: https://cep.health/media/uploaded/20181015-Non-Medical-Cannabis-Rev-6.3.pdf. Accessed 2020 Mar 27.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 66 (5)
Canadian Family Physician
Vol. 66, Issue 5
1 May 2020
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cannabis in the workplace
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cannabis in the workplace
Brent Wolfrom, Victor K. Ng
Canadian Family Physician May 2020, 66 (5) 317-318;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Cannabis in the workplace
Brent Wolfrom, Victor K. Ng
Canadian Family Physician May 2020, 66 (5) 317-318;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • What do we know about the risks of impairment?
    • What about risks from other medications?
    • Conclusion
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Le cannabis en milieu de travail
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Training policy limits career exploration in family medicine
  • Our role in making the Canadian health care system one of the world’s best
  • Food for thought, feeding the medical soul: COVID-19 pandemic lessons and reflections
Show more Commentary

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire